Gastric/GE Junction Cancer – Howard Hochster, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

Gastric/GE Junction Cancer – Howard Hochster, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

Friday June 21, 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Howard Hochster, MD, Professor of Medicine Associate Director for Clinical Research and Director, GI Oncology, Rutgers Cancer Institute, discuss gastric/GE junction cancer clinical highlights from ASCO 2019.

Non Small Cell Lung Cancer (NSCLC) – Edward Garon, MD, and Robert Figlin, MD, discuss promising agents in development for the management of NSCLC from ASCO20

Thursday June 11, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

Waldenstrom macroglobulinemia – Constantine Tam, MD, and Robert Figlin, MD, discuss recent clinical advances in the treatment of Waldenstrom macroglobulinemia from ASCO20

Monday June 8, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia from ASCO20

Featured Videos

Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management

Edward Garon, MD, discusses length of use when combining I-O with chemotherapy in 1st line NSCLC

Dana Chase, MD, FACOG, on interpretations of the overall survival results of the Phase 3 SOLO2 study